<DOC>
	<DOCNO>NCT01587430</DOCNO>
	<brief_summary>The goal : evaluate role high dose ara-c plus idarubicin mitoxantrone consolidation follow maintenance set high total cumulative anthracyclines dose ( 720-660 mg/m2 ) .</brief_summary>
	<brief_title>3 Anthracyclines , 2 Types Consolidation With Different ARA-C Doses Maintenance Adult Acute Myeloid Leukemia</brief_title>
	<detailed_description>In previous Russian AML multicenter study show escalation ARA-C dose ( 5,6 g 72 g 4 induction/consolidation course ) parallel anthracyclines dose reduction ( 630 mg/m2 285 mg/m2 ) improve survival , decrease feasibility . In ongoing trial try learn whether anthracyclines dose escalation ( 720-660 mg m2 ) equivalise standard ( 5,6 g 4 induction/consolidation course ) high ( 14,8 g ) ARA-C dos .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>de novo acute myeloid leukemia age 1560 secondary acute myeloid leukemia acute myeloid leukemia myelodysplastic syndrome Ph+ acute myeloid leukemia</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>anthracyclines</keyword>
	<keyword>high dose cytarabine</keyword>
	<keyword>maintenance</keyword>
</DOC>